Načítá se...
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial
IMPORTANCE: There is an unmet medical need for the treatment of recurrent ovarian cancer, and new approaches are needed to improve progression-free survival (PFS) and overall survival. OBJECTIVE: This phase 1/2 study evaluated the activity of alisertib in combination with weekly paclitaxel in patien...
Uloženo v:
| Vydáno v: | JAMA Oncol |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Medical Association
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6439781/ https://ncbi.nlm.nih.gov/pubmed/30347019 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.3773 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|